Navigation Links
Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
Date:6/24/2009

Study Published in Annals of Internal Medicine

CHERRY HILL, N.J., June 24 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, announced today that red yeast rice, an ingredient contained in Cinnechol, one of the Company's primary supplement products, has been recently proven to decrease levels of low-density lipoprotein, or LDL cholesterol, in dyslipidemic patients. LDL cholesterol is known more informally as "bad" cholesterol. Red yeast rice, which has been used in Ayurvedic medicine and China as a dietary supplement for centuries, contains a compound (monacolin K) that is identical in chemical composition to lovastatin, a commonly prescribed cholesterol-lowering drug.

A recent study titled "Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial," led by cardiologists Dr. David Becker and Dr. Ram Gordon and published in the Annals of Internal Medicine, showed that a diet and exercise regimen that included red yeast rice reduced LDL cholesterol by an average of 27.3%, compared to 5.7% for the control group. Moreover, the study showed that red yeast rice can decrease LDL cholesterol without increasing pain levels.

"Many synthetic statins have been derived from red yeast rice and other naturally occurring phytochemicals," stated Robert Bowker, co-inventor of Cinnechol and President of Knock-Out Technologies, Ltd., a wholly owned subsidiary of Nuvilex. "Red yeast rice, among others, is a bona fide naturally occurring statin. Cinnechol--along with diet and exercise--can help individuals maintain normal cholesterol levels and promote cardiovascular health."

Cinnechol, which contains red yeast rice extract as well as a blend of other ingredients known to improve cardiovascular function (including niacin and guggul gum extract), may provide a natural alternative for those who have high cholesterol and are intolerant of, or elect not to take, statin drugs. Cinnechol can be purchased online by visiting www.cinnechol.com.

"Red yeast rice has now been more thoroughly researched and recognized as an important tool for safely normalizing blood lipids, especially LDL cholesterol," reported Cinnechol co-inventor Steven Kushner, Ph.D. "Cinnechol, by combining Red Yeast Rice with several cardiovascular beneficial synergists, also helps promote healthy total cholesterol levels, improved HDL (beneficial cholesterol) levels, and better blood viscosity."

About Cinnechol

Cinnechol, an ingestible capsule made of all-natural ingredients, is manufactured and sold by Cinnechol, Inc. (a wholly owned subsidiary of Nuvilex, Inc.). Cinnechol is designed to help maintain normal cholesterol levels and to support normal cardiovascular function. Cinnechol, along with a healthy diet and exercise regimen, is intended to serve as a dietary supplement to help individuals manage numerous cardiovascular and metabolic disorders (including dyslipidemia, hypertension, hypoglycemia, and hyperglycemia).

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Amy Glynn/Ashleigh Barreto
    The Ruth Group
    Ph: 646-536-7023/7028
    Email: aglynn@theruthgroup.com
    Email: abarreto@theruthgroup.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream
2. Nuvilex Featured in Wall Street Reporter Interview
3. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
4. Nuvilex Launches Video Marketing Campaign
5. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
6. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
7. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
8. Nuvilex, Inc. Announces Monthly Investor Conference Call
9. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
10. Nuvilex, Inc. Announces Investor Conference Call and Open House
11. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... , ... April 30, 2016 , ... Orlando-based Maximized Living ... they go for gold in Rio. Under the care of Maximized Living doctors ... , In an unprecedented showing, Maximized Living is sending the largest contingent of elite ...
(Date:4/29/2016)... ... April 29, 2016 , ... Since launching its annual volunteer ... serving the footwear industry, has broken all previous participation records in its first ... 23 states during the months of April and May, the 2016 Footwear Cares ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) ... with sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, ... Run and Walk and 1-mile walk were held to increase awareness about Lyme ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... that student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 ... Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee Award for ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
Breaking Medicine Technology: